In Context
One in eight women will be diagnosed with breast cancer during their lifetime. Early detection significantly improves patient outcomes, making breast cancer the most treatable cancer. Yet, it remains the leading cause of cancer-related deaths among women.
The Blue Box Biomedical Solutions is changing this. The company has developed an In Vitro Diagnostic (IVD) device that detects breast cancer biomarkers in a urine sample, non-invasive, painless, and with a projected Negative Predictive Value of 99.7%, compared to 95.6% for mammography. The device aims to initially complement mammogram screening when an inconclusive result is obtained, reducing unnecessary biopsies. Long-term, however, it has the potential to redefine the standard of care for breast cancer screening entirely.